AFP's fact-checks cited as benchmark by German study

Germany’s respected Grimme institute has just published a comparative analysis of fact-checking organisations in the country, which highlights the quality of Agence France-Presse’s digital verification production.

Anglais
05/29/2025 06:13
Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect

Revolutionary Platform Sets New Benchmark for Transparency and Compliance in Diagnostic AI As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry’s first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning. The technology is backed by over 15 years of experience and millions of successfully processed samples with >9...

05/14/2025 06:05
Reply Presents “App to the Future”: A New AI-Scape Room Experience Powered by Microsoft AI and Low-Code Solutions

Reply, a global systems integrator and technology consulting firm, introduces “App to the Future” an immersive “AI-Scape Room” an immersive escape room experience powered by Microsoft Copilot, Azure AI, and Power Platform, designed to explore the full potential of AI and low-code tools in a unique and engaging way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513072546/en/The experience builds on Reply’s AI-Scape Room focused on...

05/14/2025 06:14
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agre...

04/30/2025 22:00
Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies

Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world. “Over the past...

05/23/2025 08:05
Reply Announces the Jury for the First AI Music Contest: Finalists Will Perform Live on Stage at Kappa FuturFestival in Turin

Reply, an international group specialized in the creation of new business models enabled by Artificial Intelligence and driven by a strong culture of innovation, is expanding its creative experimentation initiatives this year with the launch of the AI Music Contest. Organised in collaboration with Kappa FuturFestival, one of Europe’s leading electronic music festivals, the competition is open to creatives and innovators who use AI technologies to explore new forms of integration between sound a...

06/12/2025 12:08
Volvo Cars and HCLTech Collaborate to Drive Engineering Transformation

HCLTech, a leading global technology company, today announced that Volvo Cars has chosen HCLTech as one of its strategic suppliers for engineering services. Volvo Cars has been at the forefront of automotive innovation for many years and has set out to shape the future of mobility with strong ambitions on sustainable growth, as it seeks to offer clients the freedom to move in a personal, sustainable and safe way. Drawing on an established relationship in digital and PLM services, this agree...